AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vera Therapeutics, Inc. Director's Dealing 2024

Jan 8, 2024

31944_dirs_2024-01-08_62056433-4676-4c5d-83c1-4344c6cf1ceb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2024-01-03

Reporting Person: Brenner Robert (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-03	Stock Option (right to buy)	$15.36	A	350000	Acquired	2034-01-02	Class A Common Stock (350000)	Direct

Footnotes

F1: 1/4 of the shares subject to the option vest on January 3, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date.